Stock of the Day

Biogen (BIIB)

$235.40

+$0.05 (+0.0%)

Market Cap: $34.74B

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Bull Case

Here are some ways that investors could benefit from investing in Biogen Inc.:

• Biogen Inc. recently released 52-week Phase 2 data for litifilimab in cutaneous lupus erythematosus, demonstrating sustained improvements in skin disease activity and a well-tolerated safety profile, which has reinforced investor confidence in the company's immunology pipeline and contributed to a 90-day share price return of 17.6%.
• J.P. Morgan upgraded Biogen Inc. to Overweight from Neutral on October 12, 2026, and raised its price target to $300 from $210, citing an increasingly compelling catalyst path and highlighting upcoming 2027 clinical milestones for felzartamab and litifilimab as potential value drivers.
• The stock is currently trading at $235.35, which is near its 52-week high of $240.99, indicating strong recent momentum and a year-to-date share price gain of 26.9% that contrasts with broader market declines over longer periods.
• Biogen Inc. has consistently beaten earnings expectations, reporting $3.60 earnings per share for the quarter ended July 29, 2026, which exceeded the consensus estimate of $2.94 by $0.66, while revenue of $2.74 billion also surpassed analyst estimates of $2.46 billion.
• Institutional investors have shown significant recent interest, with the State of Alaska Department of Revenue increasing its holdings by 1,393.7% in the third quarter and Mather Group LLC boosting its position by 2,194.3%, suggesting strong conviction from major financial entities.

Biogen Bear Case

Investors should be bearish about investing in Biogen Inc. for these reasons:

• Analysts expect a sharp double-digit decline in earnings per share for the upcoming third-quarter 2026 results, which are scheduled to be reported on October 28, 2026, creating near-term uncertainty and potential downside risk for the stock.
• The consensus price target for Biogen Inc. is $231.07 as of October 10, 2026, which is slightly below the current stock price of $235.35, suggesting that the stock may be trading above the average analyst valuation and offering limited upside potential relative to the consensus view.
• Short interest in Biogen Inc. has increased to 5,965,892 shares as of September 30, 2026, representing 4.05% of the float, indicating that a significant portion of investors are betting against the stock's future performance.
• Biogen Inc. has a debt-to-equity ratio of 0.39, which, while manageable, indicates a level of leverage that could become a concern if interest rates rise or if the company faces unexpected financial pressures, potentially impacting its financial flexibility.
• The company's revenue growth has slowed, with year-over-year revenue growth of 3.4% in the most recent quarter, down from higher growth rates in previous periods, suggesting that the company may be facing challenges in sustaining its growth trajectory.

Recent News

• Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade) (seekingalpha.com)
• JP Morgan Upgrades Biogen to Overweight from Neutral (msn.com)
• Citi Remains a Hold on Biogen (BIIB) (theglobeandmail.com)
• Biogen’s Quarterly Earnings Preview: What You Need to Know (barchart.com)
• BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300 (finance.yahoo.com)
• Biogen Upgraded to Buy at J.P. Morgan. How the Stock Could Rise 28%. (finance.yahoo.com)
• Biogen (BIIB) Could Be 5% Undervalued After 52 Week Lupus Data (finance.yahoo.com)
• What Biogen (BIIB)'s 52-Week Litifilimab CLE Data Means For Shareholders (finance.yahoo.com)
• Biogen Rises After Analyst Upgrade Highlights 2027 Pipeline Catalysts (quiverquant.com)
• Stocks making the biggest moves premarket: Salesforce, First Solar, Biogen & more (cnbc.com)